Translational Development Acquisition

Translational Development Acquisition ROE

The Return on Equity (ROE) of Translational Development Acquisition (TDAC) as of Nov 4, 2026 is 3.63 %. In the previous year, Return on Equity (ROE) was -0.04 % — a change of -8,734.12% (higher).

ROE

3.63 %

YoY

-8,734.12%

Last updated:

In 2025, Translational Development Acquisition's return on equity (ROE) was 3.63 %, a -8,734.12% increase from the -0.04 % ROE in the previous year.

The Translational Development Acquisition ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2022
319.62 USD
Jan 1, 2023
95.65 USD
Jan 1, 2024
-0.04 USD
Jan 1, 2025
3.63 USD
The Translational Development Acquisition ROE history
YEARROEYoY
3.63 %-8,734.12%
-0.04 %-100.04%
95.65 %-70.08%
319.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Translational Development Acquisition Stock analysis

What does Translational Development Acquisition do? Translational Development Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company has not selected any specific business combination target and has not engaged in any substantive discussions with potential targets. It has neither generated revenues nor conducted any operations since its formation. The firm's business model relies on identifying and executing a future business combination to create value for its shareholders. The company's primary revenue source will come from the successful completion of a business combination, which typically involves acquiring a target company or asset. As a blank check company, it does not operate any business or generate income until a merger or acquisition is finalized. The firm's investors, who purchase shares during its IPO, expect the company to identify and acquire a target business that will provide returns on their investment. Translational Development Acquisition Corp is structured as a special purpose acquisition company (SPAC) that has not yet identified a target business. Its success depends entirely on finding and merging with a suitable company within the timeframe specified in its prospectus. The firm's investors are the primary buyers of its shares, anticipating capital appreciation once a business combination is executed. Translational Development Acquisition is one of the most popular companies on Eulerpool.

ROE Details

Decoding Translational Development Acquisition's Return on Equity (ROE)

Translational Development Acquisition's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Translational Development Acquisition's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Translational Development Acquisition's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Translational Development Acquisition’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Translational Development Acquisition stock

Return on Equity (ROE) of Translational Development Acquisition is 3.63 % in 2025.

Return on Equity (ROE) of Translational Development Acquisition changed from -0.04 % to 3.63 %, representing a -8,734.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Translational Development Acquisition since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Translational Development Acquisition with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Translational Development Acquisition

All Key Metrics — Translational Development Acquisition